Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Latest Information Update: 16 Jun 2025
At a glance
- Drugs Anti-CD20 monoclonal antibody (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms Veneto-STOP
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 1 May 2025 to 1 May 2026.
- 10 Jun 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2026.
- 30 May 2025 According to Adaptive Biotechnologies media release, data from this study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago.